Amgen says obesity drug caused up to 20% weight loss

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial. But shares of the company fell on Tuesday,
Amgen drug leads to up to 20% weight loss in trial
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.
Amgen’s stock slides 7.8% premarket after weight-loss drug data lags analyst expectations
Amgen Inc.’s stock AMGN tumbled 7.8% in early trade Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss
Amgen posts mid-stage data for weight loss therapy
Amgen (NASDAQ:AMGN) announced Tuesday that its experimental weight loss therapy, MariTide, generated up to ~20% of weight loss on average in roughly over a year in a Phase 2 trial for people living with obesity or overweight but without Type 2 diabetes.
Wall Street awaits Amgen weight-loss drug data expected to move shares
Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo Nordisk .
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
Wall Street Journal12m
Amgen Drug Cut Weight in Closely Watched Study
A highly-anticipated obesity drug candidate from biotech Amgen helped patients shed a significant amount of weight in a mid-stage study. Subjects taking Amgen’s MariTide lost 20% of their body ...
Amgen's Bids for Judgments Rebuffed in Cancer-Drug Damages Case
Amgen Inc. lost requests for several judgments in Lindis Biotech GmbH’s patent-infringement lawsuit seeking damages for sales of the leukemia treatment Blincyto, according to a federal judge’s mixed ...
Evan Seigerman’s Buy Rating on Amgen Driven by Positive MariTide Outlook and Undervaluation
BMO Capital analyst Evan Seigerman has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...
STAT11d
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious
Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...
FierceBiotech13d
Hidden data on obesity prospect wipe $12B off Amgen market cap
A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab ...
BioPharma Dive4d
Amgen picks prolific biotech founder Chang as new top scientist
Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...
Equities Analysts Issue Forecasts for Amgen FY2024 Earnings
Investment analysts at Zacks Research lifted their FY2024 earnings per share (EPS) estimates for shares of Amgen in a ...